NCT03235167Unknown1 期
Cytidine-phosphate-guanosine (CpG) DNA in Hepatocellular Carcinoma Combination Therapy
Dalian University0 个研究点目标入组 100 人开始时间: 2017年10月最近更新:
适应症
干预措施
相关药物
试验速览
- 阶段
- 1 期
- 发起方
- 入组人数
- 100
- 主要终点
- survival time
研究概览
简要总结
to observe the outcome of hepatocellular carcinoma patients under the combination treatment of transcatheter arterial chemoembolization (TACE) and CpG DNA
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Factorial
- 主要目的
- Treatment
- 盲法
- Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
入排标准
- 年龄范围
- 55 Years 至 75 Years（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •TNM (tumor node metastasis ) staging with non distant metastasis; no other tumors
排除标准
- •having received previous treatment for liver cancer
研究组 & 干预措施
CpG DNA
Experimental
CpG DNA concentrate
干预措施: CpG DNA (Drug)
CpG DNA
Experimental
CpG DNA concentrate
干预措施: transcatheter arterial chemoembolization (Procedure)
placebo
Placebo Comparator
placebo concentrate
干预措施: transcatheter arterial chemoembolization (Procedure)
placebo
Placebo Comparator
placebo concentrate
干预措施: Placebo - Concentrate (Drug)
结局指标
主要结局
survival time
时间窗: 5 years
metastasis free survival time
时间窗: 5 years
次要结局
未报告次要终点
研究者
相似试验
招募中
不适用
Cohort Study of Patients With Hepatocellular Carcinoma and Circulating Tumor DNA Monitoring of ChemoembolizationCirculating Tumor DNAHepatocellular Carcinoma Non-resectableTransarterial ChemoembolizationNCT05390112University Hospital, Rouen167
Unknown
1 期
GPC3-targeted CAR-T Cell for Treating GPC3 Positive Advanced HCCHepatocellular CarcinomaNCT04121273The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School20
已完成
不适用
Pharmacogenetic Study in Hepatocellular Carcinoma Patients.Hepatocellular CarcinomaNCT05291338Rehab Werida107
招募中
不适用
Biomarkers and Molecular Mechanism Study of Hepatocellular Carcinoma After Radical Resection and Conversion TherapyHepatocellular CarcinomaNCT06382103Shanghai Zhongshan Hospital240
已完成
不适用
Targeted Treatment Plus Tislelizumab and HAIC for Advanced CRCLM Failed From Standard Systemic TreatmentLiver Metastasis Colon CancerMSSNCT06199232Peking University47